Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03818776 | Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC | terminated | Early Phase 1 | 7 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT02654587 | OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure(ATALANTE-1) | terminated | Phase 3 | 219 | OSE ImmunotherapeuticsINDUSTRY | 10 | Feb 2, 2024 |
| clinicaltrials |
| NCT04676386 | Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy(BEACON-LUNG) | terminated | — | 29 | Addario Lung Cancer Medical InstituteOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT00617656 | Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma(BREC) | terminated | Phase 3 | 382 | Spanish Lung Cancer GroupOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05176925 | Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC | terminated | Phase 2 | 5 | Fudan UniversityOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04524195 | PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03840902 | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 153 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Jan 16, 2024 | clinicaltrials |
| NCT05088967 | Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer | terminated | Phase 1 | 6 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03492801 | Collection of Blood Samples in Patients With Non-small Cell Lung Cancer | terminated | — | 10 | University of Southern CaliforniaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03870529 | High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer | terminated | Early Phase 1 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04099836 | Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib | terminated | Phase 2 | 7 | Duke UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT01514864 | Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | terminated | Phase 2 | 19 | Bristol-Myers SquibbINDUSTRY | 7 | Dec 19, 2023 | clinicaltrials |
| NCT03386929 | Survival Prolongation by Rationale Innovative Genomics(SPRING) | terminated | Phase 1 / Phase 2 | 15 | Worldwide Innovative Network AssociationOTHER | 4 | Dec 18, 2023 | clinicaltrials |
| NCT04785365 | Long-Term Follow-Up Study of Patients Receiving ATL001 | terminated | Phase 2 | 1 | Achilles Therapeutics UK LimitedINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04556435 | Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy | terminated | — | 51 | Breathe BioMedical IncINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02826161 | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer(CanStem43L) | terminated | Phase 3 | 4 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT03871153 | Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer | terminated | Phase 2 | 7 | Greg Durm, MDOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03228186 | Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 40 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04739358 | CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC | terminated | Phase 1 / Phase 2 | 2 | Criterium, Inc.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05414123 | A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide(FORESEE) | terminated | — | 40 | Biocept, Inc.INDUSTRY | 1 | Oct 16, 2023 | clinicaltrials |
| NCT03951012 | Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy | terminated | — | 29 | Muhammad FurqanOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT04040244 | Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis | terminated | N/A | 16 | Wake Forest University Health SciencesOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04082988 | Early Response Evaluation in NSCLC Patients Treated With Immunotherapy | terminated | N/A | 9 | The Netherlands Cancer InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma(ENSIGN) | terminated | Phase 2 | 11 | Eric Bernicker, MDOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | terminated | — | 20 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 5 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03425006 | Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer | terminated | Phase 2 | 23 | University of PennsylvaniaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04422392 | Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer | terminated | Phase 2 | 93 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT03317496 | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 67 | PfizerINDUSTRY | 8 | Aug 29, 2023 | clinicaltrials |
| NCT05106335 | A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC | terminated | Phase 3 | 1 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT03417882 | GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC | terminated | Phase 2 | 20 | BrightPath BiotherapeuticsINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04971187 | Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT04705025 | Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer(BNT001) | terminated | N/A | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT02710396 | Genetic Predictors of Benefit to Pembrolizumab | terminated | Phase 2 | 19 | Columbia UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT02919449 | Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab | terminated | Phase 1 | 2 | Vyriad, Inc.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT03927573 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker | terminated | Phase 1 | 23 | AvenCell Europe GmbHINDUSTRY | 1 | Jul 10, 2023 | clinicaltrials |
| NCT02584634 | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | terminated | Phase 1 / Phase 2 | 43 | PfizerINDUSTRY | 5 | Jul 7, 2023 | clinicaltrials |
| NCT00750698 | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib | terminated | Phase 2 | 8 | Syndax PharmaceuticalsINDUSTRY | 1 | Jul 6, 2023 | clinicaltrials |
| NCT03805841 | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions(RAIN) | terminated | Phase 2 | 41 | Rain Oncology IncINDUSTRY | 3 | Jun 28, 2023 | clinicaltrials |
| NCT04381494 | Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.(ON TRAX) | terminated | Phase 4 | 40 | AstraZenecaINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02335944 | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | terminated | Phase 1 / Phase 2 | 177 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 18, 2023 | clinicaltrials |
| NCT05153408 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | terminated | Phase 1 | 20 | Blueprint Medicines CorporationINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03509584 | Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients | terminated | Phase 1 | 6 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jun 15, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 15, 2024source: clinicaltrials